Skip to content

STEDIPHAR

Active Private limited companyfounded 2002active for 24 yearsNieuwpoortsesteenweg 70, 8400 OstendKBO/BCE: BE 0477.059.361

Lifetime

20 annual accounts with figures on one time axis, 24 filings since 2002
peak of €391,214 in 2025
€391,214▲ 11.8%
peak of €401,190 in 2016
€207,443▼ 8.3%
peak of €325,335 in 2025
€325,335▲ 9.2%
€760,475▼ 24.3%
peak of 1.9 FTE in 2008
1.9 FTE▲ 26.7%
Board1 name since 2021
1 director
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Staff from 1.5 FTE to 1.9 FTEDebts from €1.0m to €760,475Cash from €708,064 to €53,865

Key points

from the 2025 annual accounts

Equity

€325,335 ▲ 9.2%

STEDIPHAR has made a profit in every financial year since 2006.

Turnover

≈ €1.3m estimated

The abbreviated format states no turnover.

Debts

€760,475 70% of the balance sheet
Suppliers 45%Taxes and wages 3%Other 52%

Of this, €760,320 falls due within a year.

Investments

€18,753 1.7 times depreciation
20212022202320242025

Green is investment, beige is depreciation. Machinery stands 62.2% higher than in 2024.

Filings

24 annual accounts since 2002
AprilJune31 JulyOctober20102020

Ten of the last ten came late. The 2019 accounts came in latest, 63 days after the end of the period.

Position in the sector

€207,443

Higher net result than 86% of companies in retail trade. The sector median is €37,977, over 13,298 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,821 companies had the same profile as STEDIPHAR has now. Each dot stands for 10 companies, two years later.

95.1%
were still trading
3.8%
stopped another way
1.0%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,821 companies, not a prediction for STEDIPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0477059361
2 managers resigning, 2 directors reappointed (manager) and (manager) resign · (director) and (director) reappointed · and act as permanent representatives · General meeting of 17-08-2022 · Gazette deed
First establishment APOTHEEK S. MEULEMEESTER, Nieuwpoortsesteenweg 70, Ostend
Incorporation published on 23-03-2002 · Gazette deed
All 32 events

Comparable companies

same main activity, similar in size and age
Company
STEDIPHAR Ostend €1.1m €391,214 30.0% 1.9
APOTHEEK DENECKERE-DEMARE Ostend €1.0m €411,228 57.4% 2
WEZEFARMA Rotselaar €1.0m €401,976 37.1% 2
PHARMALIS Neufchâteau €1.1m €336,675 7.8% 1.9
Apotheek Reynders Ostend €0.9m €389,372 6.9% 1.8
DECORTE APOTHEEK Torhout €1.1m €362,147 30.1% 2.1
APOTHEEK MAERTENS Wevelgem €1.3m €382,222 26.3% 1.8

These companies have the same main activity as STEDIPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €924,000 and €1.3m, founded between 1997 and 2006.

Official details

Source: KBO
Status
Active since 11-03-2002Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.115.608.2068400 Ostend, since 13-11-2002
Financial year end
31 December
Peppol
Reachable since 15-07-2025
Company details

Annual accounts 2025

€1.1m▼ 16.6%
Employeeson 31-12-2025
2=
Filing
Filed on 27-08-2026
Financials

Insights on STEDIPHAR

STEDIPHAR files the abbreviated format. That format states no turnover. The gross margin rose from €216,129 in 2006 to €391,214 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about STEDIPHAR

What is the company number of STEDIPHAR?
The company number of STEDIPHAR is 0477.059.361. The VAT number is the same number with BE in front: BE 0477.059.361.
Where is STEDIPHAR based?
The registered office is at Nieuwpoortsesteenweg 70, 8400 Ostend.Company details
What does STEDIPHAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of STEDIPHAR?
STEDIPHAR is a private limited company (BV).
When was STEDIPHAR founded?
STEDIPHAR was founded on 11-03-2002.
Is STEDIPHAR still active?
Yes, STEDIPHAR is an active enterprise in the KBO register.
How many employees does STEDIPHAR have?
STEDIPHAR had an average of 1.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does STEDIPHAR fall under?
In its 2025 annual accounts, STEDIPHAR states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of STEDIPHAR?
The turnover in financial year 2025 is about €1.3m. This figure is estimated from the gross margin of €391,214 and 42 comparable companies (NACE 477). It probably lies between €1.1m and €1.9m.
Is STEDIPHAR profitable?
In financial year 2025, STEDIPHAR made a profit of €207,443.
Where can I find the annual accounts of STEDIPHAR?
STEDIPHAR filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of STEDIPHAR due?
STEDIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.